Reimbursement Support for Neuraceq®
Neuraceq® is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline. Neuraceq® is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterization of patients assessed for treatment eligibility with newly approved anti-amyloid drugs.
We Are Here to Support You
For questions related to coding, coverage, or payment using Neuraceq® for Amyloid PET imaging, contact our Reimbursement team.
Reimbursement Resources
Includes Neuraceq® billing codes and details about access and reimbursement support services
If Prior Authorization is required, see guidance on what is needed to submit a request
View a sample claim form for a physician office and Independent Diagnostic Testing Facility (IDTF)
View guidance for a sample claim form for a Hospital Outpatient facility
On July 15, 2025, The Centers for Medicare & Medicaid Services (CMS) proposed a change in the payment threshold for all diagnostic radiopharmaceuticals from $630 to $655 under Hospital Outpatient Prospective Payment Systems (OPPS).
Life Molecular Imaging strongly supports the use of Average Sales Price (ASP) to calculate reimbursement rates, and encourages you to submit a public comment in favor of ASP instead of MUC, as ASP is more reflective of the actual cost of the product and would benefit your site.
October 13, 2023
Centers for Medicare & Medicaid Services (CMS) retires the NCD, which eliminates CED and the 1 scan per lifetime patient limit
US-Neuraceq-25-00002
The information contained in Neuraceq.com/hcp is intended for healthcare professionals in the United States only. If you are a US healthcare professional, click the "Continue" button below.
Yes, I am a US healthcare professional and would like to continue.
This will close in 0 seconds
PRODUCT INDICATIONS AND USE: NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.
NEURACEQ IMPORTANT SAFETY INFORMATION:
CONTRAINDICATIONS: None
WARNINGS AND PRECAUTIONS:
ADVERSE REACTIONS:
USE IN SPECIFIC POPULATIONS:
OVERDOSAGE:
In the event of administration of a radiation overdose with NEURACEQ, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to NEURACEQ administration, please read the full Prescribing Information for additional Important Safety Information.
SUSPECTED ADVERSE REACTIONS: please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program
